Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of thromboxane inhibitors in asthma.
Expert Opin Investig Drugs 2002; 11(2):275-81EO

Abstract

This paper reviews the role of thromboxane A(2) (TXA(2)) in the pathogenesis of pulmonary allergies, particularly asthma. The potential of TXA(2) modifiers in the prevention and/or treatment of pulmonary allergies is also discussed. Bronchial asthma is characterised by reversible airway obstruction, bronchial hyperresponsiveness and inflammation. Several studies have elucidated the role of arachidonic acid metabolites (leukotrienes, prostaglandins and TXA(2)) in the pathogenesis of asthma. Among those mediators, TXA(2) has attracted attention due to its strong physiological activity. Indeed, TXA(2) demonstrates not only potent bronchoconstrictive activity but is also believed to be involved both in late asthmatic responses and in bronchial hyperresponsiveness, a typical feature of this disease. Several thromboxane receptor antagonists (TXRAs) and thromboxane synthase inhibitors (TXSIs) have been studied with the aim of reducing or preventing asthma. As double-blind, placebo-controlled clinical trials have proven the efficiency of some TXA(2) modifiers in treating asthma, the TP receptor antagonist seratrodast (AA-2414) and the thromboxane synthase inhibitor ozagrel hydrochloride (OKY-046) are now available as anti-asthmatic agents in Japan. Moreover, seratrodast and ramatroban (BAY-U-3405), another thromboxane receptor antagonist, are currently under Phase III clinical evaluation in the US for the treatment of asthma.

Authors+Show Affiliations

Department of Medicinal Chemistry, University of Liège, 1 avenue de l'Hôpital, B36, 4000 Liège, Belgium. Jean-Michel.Dogne@ulg.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11829716

Citation

Dogné, Jean-Michel, et al. "Therapeutic Potential of Thromboxane Inhibitors in Asthma." Expert Opinion On Investigational Drugs, vol. 11, no. 2, 2002, pp. 275-81.
Dogné JM, de Leval X, Benoit P, et al. Therapeutic potential of thromboxane inhibitors in asthma. Expert Opin Investig Drugs. 2002;11(2):275-81.
Dogné, J. M., de Leval, X., Benoit, P., Rolin, S., Pirotte, B., & Masereel, B. (2002). Therapeutic potential of thromboxane inhibitors in asthma. Expert Opinion On Investigational Drugs, 11(2), pp. 275-81.
Dogné JM, et al. Therapeutic Potential of Thromboxane Inhibitors in Asthma. Expert Opin Investig Drugs. 2002;11(2):275-81. PubMed PMID: 11829716.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic potential of thromboxane inhibitors in asthma. AU - Dogné,Jean-Michel, AU - de Leval,Xavier, AU - Benoit,Patricia, AU - Rolin,Stephanie, AU - Pirotte,Bernard, AU - Masereel,Bernard, PY - 2002/2/7/pubmed PY - 2003/7/26/medline PY - 2002/2/7/entrez SP - 275 EP - 81 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 11 IS - 2 N2 - This paper reviews the role of thromboxane A(2) (TXA(2)) in the pathogenesis of pulmonary allergies, particularly asthma. The potential of TXA(2) modifiers in the prevention and/or treatment of pulmonary allergies is also discussed. Bronchial asthma is characterised by reversible airway obstruction, bronchial hyperresponsiveness and inflammation. Several studies have elucidated the role of arachidonic acid metabolites (leukotrienes, prostaglandins and TXA(2)) in the pathogenesis of asthma. Among those mediators, TXA(2) has attracted attention due to its strong physiological activity. Indeed, TXA(2) demonstrates not only potent bronchoconstrictive activity but is also believed to be involved both in late asthmatic responses and in bronchial hyperresponsiveness, a typical feature of this disease. Several thromboxane receptor antagonists (TXRAs) and thromboxane synthase inhibitors (TXSIs) have been studied with the aim of reducing or preventing asthma. As double-blind, placebo-controlled clinical trials have proven the efficiency of some TXA(2) modifiers in treating asthma, the TP receptor antagonist seratrodast (AA-2414) and the thromboxane synthase inhibitor ozagrel hydrochloride (OKY-046) are now available as anti-asthmatic agents in Japan. Moreover, seratrodast and ramatroban (BAY-U-3405), another thromboxane receptor antagonist, are currently under Phase III clinical evaluation in the US for the treatment of asthma. SN - 1354-3784 UR - https://www.unboundmedicine.com/medline/citation/11829716/Therapeutic_potential_of_thromboxane_inhibitors_in_asthma_ L2 - http://www.tandfonline.com/doi/full/10.1517/13543784.11.2.275 DB - PRIME DP - Unbound Medicine ER -